Top Clinical Trials companies in China by EBIT Margin

This ranking features the top 23 Clinical Trials companies in China ranked by EBIT Margin, averaging a EBIT Margin of -4,456.21%, for January 15, 2025.

China

Clinical Trials

#	Name	EBIT Margin	Reported Date	Stock Price	Change	Country
1	Akeso, Inc. 1 9926.HK	44.84%	Dec. 31, 2023	USD 7.28	2.32%	China
2	Hangzhou Tigermed Consulting Co., Ltd. 2 3347.HK	35.33%	Dec. 31, 2023	USD 3.72	2.09%	China
3	HBM Holdings Limited 3 2142.HK	29.67%	Dec. 31, 2023	USD 0.34	-0.77%	China
4	Mega Genomics Limited 4 6667.HK	24.65%	Dec. 31, 2023	USD 1.18	-0.89%	China
5	Joinn Laboratories(China)Co.,Ltd. 5 6127.HK	21.46%	Dec. 31, 2023	USD 1.06	2.98%	China
6	Shanghai Henlius Biotech, Inc. 6 2696.HK	11.71%	Dec. 31, 2023	USD 2.59	-10.24%	China
7	Kindstar Globalgene Technology, Inc. 7 9960.HK	5.31%	Dec. 31, 2023	USD 0.15	-0.02%	China
8	TOT BIOPHARM International Company Limited 8 1875.HK	-4.17%	Dec. 31, 2023	USD 0.24	4.98%	China
9	Lepu Biopharma Co., Ltd. 9 2157.HK	-6.93%	Dec. 31, 2023	USD 0.31	4.82%	China
10	InnoCare Pharma Limited 10 9969.HK	-82.48%	Dec. 31, 2023	USD 0.69	3.45%	China
11	Adagene Inc. 11 ADAG	-89.22%	Dec. 31, 2023	USD 1.80	1.12%	China
12	Alphamab Oncology 12 9966.HK	-90.69%	Dec. 31, 2023	USD 0.43	4.62%	China
13	Keymed Biosciences Inc. 13 2162.HK	-95.72%	Dec. 31, 2023	USD 3.69	1.93%	China
14	Staidson (Beijing) BioPharmaceuticals Co., Ltd. 14 300204.SZ	-100.22%	Dec. 31, 2023	USD 0.95	3.28%	China
15	Burning Rock Biotech Limited 15 BNR	-124.90%	Dec. 31, 2023	USD 6.55	-6.69%	China
16	RemeGen Co., Ltd. 16 9995.HK	-138.29%	Dec. 31, 2023	USD 1.59	2.46%	China
17	Zai Lab Limited 17 9688.HK	-140.27%	Dec. 31, 2023	USD 2.49	0.18%	China
18	Hua Medicine (Shanghai) Ltd. 18 2552.HK	-265.41%	Dec. 31, 2023	USD 0.17	-0.02%	China
19	Ascentage Pharma Group International 19 6855.HK	-376.97%	Dec. 31, 2023	USD 5.19	2.25%	China
20	JW (Cayman) Therapeutics Co. Ltd 20 2126.HK	-434.60%	Dec. 31, 2023	USD 0.17	2.32%	China
21	Jacobio Pharmaceuticals Group Co., Ltd. 21 1167.HK	-552.28%	Dec. 31, 2023	USD 0.17	1.52%	China
22	Abbisko Cayman Limited 22 2256.HK	-2,252.95%	Dec. 31, 2023	USD 0.57	1.58%	China
23	ImmuneOnco Biopharmaceuticals (Shanghai) Inc. 23 1541.HK	-97,910.62%	Dec. 31, 2023	USD 0.62	4.32%	China

Frequently Asked Questions

Which Clinical Trials company in China has the highest EBIT Margin ?

The Clinical Trials company in China with the highest EBIT Margin is Akeso, Inc. (HKSE: 9926.HK) at 44.84%.
Which Clinical Trials company in China has the lowest EBIT Margin ?

The Clinical Trials company in China with the lowest EBIT Margin is ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKSE: 1541.HK) at -97,910.62%.

What are the top 10 Clinical Trials companies in China by EBIT Margin ?

The top 10 Clinical Trials companies in China by EBIT Margin are Akeso, Inc., Hangzhou Tigermed Consulting Co., Ltd., HBM Holdings Limited, Mega Genomics Limited, Joinn Laboratories(China)Co.,Ltd., Shanghai Henlius Biotech, Inc., Kindstar Globalgene Technology, Inc., TOT BIOPHARM International Company Limited, Lepu Biopharma Co., Ltd. and InnoCare Pharma Limited.
What are the bottom 10 Clinical Trials companies in China by EBIT Margin ?

The bottom 10 Clinical Trials companies in China by EBIT Margin are ImmuneOnco Biopharmaceuticals (Shanghai) Inc., Abbisko Cayman Limited, Jacobio Pharmaceuticals Group Co., Ltd., JW (Cayman) Therapeutics Co. Ltd, Ascentage Pharma Group International, Hua Medicine (Shanghai) Ltd., Zai Lab Limited, RemeGen Co., Ltd., Burning Rock Biotech Limited and Staidson (Beijing) BioPharmaceuticals Co., Ltd..